期刊文献+

评估肝纤维化进展相关的血清标志物研究现状 被引量:4

The current research on evaluating the progress of liver fibrosis by serum markers
暂未订购
导出
摘要 肝纤维化是各种慢性肝病重要的病理特征,也是进一步向肝硬化发展的必经阶段,早期诊断和治疗对阻止肝纤维化发展为肝硬化具有重要意义。肝活检仍是诊断肝纤维化的金标准,但具有创性,不易动态观察,临床应用受到限制,因此需寻求理想的无创诊断方法。在过去的十年中,肝纤维化进展相关的血清标志物研究取得了很大的进展,为肝纤维化的无创诊断带来了新希望。 Liver fibrosis is not only a significant feature of various liver diseases, but also the inevitable stage to liver cirrhosis. In order to prevent the progress to cirrhosis, it is important to diagnose and treat liver fibrosis early. Liver biopsy is still the gold standard for the diagnosis of liver fibrosis. But because its invasive trait and limited repeatability, its application is restricted. Thus it is necessary to seek ideal non - invasive method. Last decade' s breakthroughs of serum markers brought new hope to the diagnosis.
作者 王燕 陆伦根
出处 《临床肝胆病杂志》 CAS 2011年第8期877-880,892,共5页 Journal of Clinical Hepatology
关键词 肝硬化 生物学标记 liver cirrhosis biological markers
  • 相关文献

参考文献1

二级参考文献43

  • 1Forns X, Ampurdanes S, Sanchez-Tapias JM, Guilera M, Sans M, Sanchez-Fueyo A. Quinto L, Joya P, Bruguera M, Rodes J.Long-term follow-up of chronic hepatitis C in patients diagnosed at a tertiary-care center. J Hepatol 2001; 35:265-271.
  • 2Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inoue O, Hashimoto E, Lefkowitch JH, Ludwig J, Okuda K. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996; 23; 1334-1340.
  • 3Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For thegroup of epidemiology of the french association for the study of the liver (AFEF). Hepatology 2000; 32:477-481.
  • 4Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatololgy 2003; 38:518-526.
  • 5Pares A, Deulofeu R, Gimenez A, Caballeria L, Bruguera M,Caballeria J, Ballesta AM, Rodes J. Serum hyaluronate reflects hepatic fibrogenesis in alcoholic liver disease and is useful as a marker of fibrosis. Hepatoloyg 1996; 24:1399-1403.
  • 6Nojgaard C, Johansen JS, Cl~ristensen E, Skovgaard LT, Price PA, Becker U. EMALD group. Serum levels of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease. J Hepatol 2003; 2:179-186.
  • 7Nojgaard C,Johansen JS, Krarup HB, Holten-Andersen M,Moiler A, Bendtsen F. Effect of antiviral therapy on markers of fibrogenesis in patients with chronic hepatitis C. Scand J Gastroenterol 2003; 38:659-665.
  • 8Murawaki Y, Ikuta Y, Koda M, Yamada S, Kawasaki H. Comparison of serum 7S fragment of type IV collagen and serum central triple-helix of type IV collagen for assessment of liver fibrosis in patients with chronic viral liver disease. J Hepatol 1996; 24:148-154.
  • 9Forns X, Ampurdanes S, Llovet JM, Aponte J, Quinto L, Martinez-Bauer E, Bruguera M, Sanchez-Tapias JM, Rodes J. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36:986-992.
  • 10Guechot J, Poupon RE, Giral P, Balkau B, Giboudeau J, Poupon R. Relationship between procollagen III aminoterminal propeptide and hyaluronan serum levels and histological fibrosis in primary biliary cirrhosis and chronic viral hepatitis C. J Hepatol 1994; 20:388-393.

共引文献21

同被引文献45

引证文献4

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部